tobemstomig (RG6139) / Roche 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tobemstomig (RG6139) / Roche
2022-000631-23: A Study of Multiple Doses of RO7247669 in Participants with Previously Untreated Unresectable or Metastatic Melanoma Estudio de Diferentes Dosis de RO7247669 en Participantes con Melanoma No Resecable o Mestatásico No Tratados Previamente

Ongoing
2
80
Europe
PD1-LAG3, RO7247669/F01-01, Solution for infusion
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Unresectable or Metastatic Melanoma Melanoma no resecable o mestatásico, Melanoma is a type of skin cancer which develops when the cells that control pigment of the skin (melanocytes) become cancerous. El melanoma es un tipo de cáncer de piel que se produce cuando las células encargadas de controlar la pigmentación de la piel (melanocitos) se vuelven cancerosas., Diseases [C] - Cancer [C04]
 
 
2022-002265-15: A Study of RO7247669 Alone or in Combination with Tiragolumab Versus Atezolizumab in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Bladder Cancer who are Ineligible for Platinum-Containing Chemotherapy

Ongoing
2
240
Europe
PD1-LAG3, tiragolumab, RO7247669/F01-01, RO5541267/F03-01, RO7092284/F03-01, Solution for infusion, Concentrate for solution for injection/infusion, Concentrate for solution for infusion, Tecentriq®
F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Previously Untreated Locally Advanced or Metastatic Urothelial Bladder Cancer, Urothelial Bladder Cancer is common type of cancer that has spread outside of the bladder to other parts of the body, this causes back pain, painful urination, frequent urination, and blood in urine., Diseases [C] - Cancer [C04]
 
 
2022-001440-18: A Study of RO7247669 plus Platinum-Based Chemotherapy vs. Pembrolizumab plus Platinum-Based Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Un estudio de RO7247669 más quimioterapia basada en platino frente a pembrolizumab más quimioterapia basada en platino en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico no tratado previamente

Not yet recruiting
2
210
Europe
PD1-LAG3, RO7247669/F01-01, Solution for infusion, Concentrate for solution for infusion, Lyophilisate for solution for infusion, Keytruda, Carboplatin, ALIMTA, Paclitaxel
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann La-Roche Ltd
Previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) Cáncer de pulmón no microcítico (CPNM) localmente avanzado o metastásico no tratado previamente, NSCLC that has spread to areas near the lungs or other organs and has not yet been treated by chemotherapy; it is the most common kind of lung cancer. CPNM que se ha extendido a zonas cercanas a los pulmones o a otros órganos y que aún no ha sido tratado con quimioterapia; es el tipo más común de cáncer de pulmón., Diseases [C] - Cancer [C04]
 
 
2021-006430-39: A Study of Immune Checkpoint Inhibitor Combinations with Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma Un estudio de combinaciones inhibidoras de puntos de control inmunitario con Axitinib en pacientes con carcinoma de células renales no tratado previamente localmente avanzado no resectable o metastásico

Not yet recruiting
2
210
Europe
tiragolumab, PD1-LAG3, Pembrolizumab, RO7092284/F03-01, RO7247669/F01-01, RO7223188, Concentrate for solution for infusion, Solution for infusion, Film-coated tablet, INLYTA®, KEYTRUDA®
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F.Hoffmann-La Roche Ltd, F.Hoffmann-La Roche Ltd
Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma Carcinoma de células renales localmente avanzado no resectable o carcinoma de células renales metastásico, Clear Cell Renal cell carcinoma (RCC), is the most common type of kidney cancer El carcinoma de células renales (CCR) de células claras es el tipo de cáncer de riñón más común, Diseases [C] - Cancer [C04]
 
 
NCT05805501: A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Active, not recruiting
2
210
Europe, US, RoW
Tobemstomig, RO7247669, Tiragolumab, Pembrolizumab, Keytruda, Axitinib, Inlyta
Hoffmann-La Roche
Renal Cell Carcinoma
05/25
10/26
NCT04785820 / 2020-004606-60: A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Jul 2024 - Sep 2024: From trial in combination with RO7247669 for metastatic esophageal squamous cell carcinoma
Active, not recruiting
2
210
Europe, RoW
Lomvastomig, RO7121661, RG7769, PD1-TIM3 BsAb, Tobemstomig, RO7247669, RG6139, PD1-LAG3 BsAb, Nivolumab, Opdivo®
Hoffmann-La Roche
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
06/25
06/25
NCT05852691: A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Recruiting
2
160
Europe, US, RoW
Tobemstomig, RO7247669, Pembrolizumab, Nab-Paclitaxel
Hoffmann-La Roche
Breast Cancer
12/25
02/26
NCT05775289: A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Active, not recruiting
2
180
Europe, US, RoW
Tobemstomig, RO7247669, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin
Hoffmann-La Roche
Non-small Cell Lung Cancer
06/24
06/26
NCT05645692 / 2022-002265-15: A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Active, not recruiting
2
210
Europe, US, RoW
Atezolizumab, Tobemstomig, RO7247669, Tiragolumab
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Urothelial Cancer
12/26
12/26
2021-002147-29: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Melanoma (Morpheus-Melanoma) Un estudio que evalúa la eficacia y seguridad de múltiples combinaciones de tratamientos en pacientes con melanoma (morfeo-melanoma)

Not yet recruiting
1/2
336
Europe
Atezolizumab, PD1-LAG3, OPDIVO, tiragolumab, ipilimumab, RO5541267, RO7247669, RO7344269, RO7092284, Concentrate for solution for infusion, Tecentriq, OPDIVO®, YERVOY 5 mg/ml concentrate for solution for infusion
Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Melanoma Melanoma, Melanoma is a form of skin cancer that begins in the cells (melanocytes) that control the pigment in your skin El melanoma es una forma de cáncer de piel que comienza en las células (melanocitos) que controlan el pigmento de la piel., Diseases [C] - Cancer [C04]
 
 
NCT05116202: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Completed
1/2
110
Europe, US, RoW
Nivolumab, Ipilimumab, RO7247669 2100 mg, Atezolizumab, Tecentriq, RO5541267, Tiragolumab, RO7092284, RO7247669 600 mg
Hoffmann-La Roche
Melanoma
09/23
05/24
NCT05908786: A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

Recruiting
1/2
150
Europe, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Tiragolumab, Tobemstomig, RO7247669
Hoffmann-La Roche
Carcinoma, Hepatocellular
09/25
09/28
NCT05419388 / 2022-000631-23: A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma

Recruiting
1/2
80
Europe, Canada, RoW
RO7247669
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Melanoma
10/25
10/25
Morpheus-Liver, NCT04524871 / 2020-001743-10: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers

Recruiting
1/2
518
Europe, US, RoW
Atezolizumab, Tecentriq, Bevacizumab 15 mg/kg, Avastin, Tiragolumab, Tocilizumab, Actemra, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg
Hoffmann-La Roche, Adagene Inc, Tempest Therapeutics, NiKang Therapeutics, Inc., Immune-Onc Therapeutics
Advanced Liver Cancers
08/26
08/26
NCT04140500: Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

Active, not recruiting
1/2
320
Europe, RoW
RO7247669
Hoffmann-La Roche
Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
12/25
12/25

Download Options